and worked in University of Bristol as a surgeon and anaesthetist, before doing postgraduate research with Tim J. Biscoe[3] on the neuropharmacology of amino acids, he was awarded his PhD in 1974.

[4][5] During postdoctoral studies at the Australian National University with David Curtis, he helped establish the role of glutamate as a central neurotransmitter and characterised its actions between AMPA, N-Methyl-D-aspartic acid (NMDA) and kainate receptor subtypes.

David was recruited as a director of Eli Lilly's neuroscience program, where he helped develop glutamate receptor approaches to brain diseases, resulting in clinical trials, e.g. for schizophrenia, some of which are ongoing.

[7] “All text published under the heading 'Biography' on Fellow profile pages is available under Creative Commons Attribution 4.0 International License.” --"Royal Society Terms, conditions and policies".

{{cite web}}: CS1 maint: bot: original URL status unknown (link) This article about a British scientist is a stub.